GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CTI BioPharma Corp (NAS:CTIC) » Definitions » Shiller PE Ratio

CTI BioPharma (CTI BioPharma) Shiller PE Ratio : (As of May. 05, 2024)


View and export this data going back to 1997. Start your Free Trial

What is CTI BioPharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


CTI BioPharma Shiller PE Ratio Historical Data

The historical data trend for CTI BioPharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CTI BioPharma Shiller PE Ratio Chart

CTI BioPharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CTI BioPharma Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CTI BioPharma's Shiller PE Ratio

For the Biotechnology subindustry, CTI BioPharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CTI BioPharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CTI BioPharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where CTI BioPharma's Shiller PE Ratio falls into.



CTI BioPharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

CTI BioPharma's E10 for the quarter that ended in Mar. 2023 is calculated as:

For example, CTI BioPharma's adjusted earnings per share data for the three months ended in Mar. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-0.1/127.3478*127.3478
=-0.100

Current CPI (Mar. 2023) = 127.3478.

CTI BioPharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201306 -1.700 98.518 -2.197
201309 -2.000 98.790 -2.578
201312 1.200 98.326 1.554
201403 -2.000 99.695 -2.555
201406 -1.900 100.560 -2.406
201409 0.300 100.428 0.380
201412 -2.700 99.070 -3.471
201503 -1.600 99.621 -2.045
201506 -1.900 100.684 -2.403
201509 -1.900 100.392 -2.410
201512 -1.300 99.792 -1.659
201603 0.120 100.470 0.152
201606 -0.710 101.688 -0.889
201609 -1.040 101.861 -1.300
201612 -0.230 101.863 -0.288
201703 -0.710 102.862 -0.879
201706 0.030 103.349 0.037
201709 -0.280 104.136 -0.342
201712 -0.330 104.011 -0.404
201803 -0.080 105.290 -0.097
201806 -0.200 106.317 -0.240
201809 -0.260 106.507 -0.311
201812 0.010 105.998 0.012
201903 -0.190 107.251 -0.226
201906 -0.190 108.070 -0.224
201909 -0.170 108.329 -0.200
201912 -0.140 108.420 -0.164
202003 -0.200 108.902 -0.234
202006 -0.190 108.767 -0.222
202009 -0.150 109.815 -0.174
202012 -0.200 109.897 -0.232
202103 -0.230 111.754 -0.262
202106 -0.210 114.631 -0.233
202109 -0.260 115.734 -0.286
202112 -0.380 117.630 -0.411
202203 -0.370 121.301 -0.388
202206 -0.210 125.017 -0.214
202209 -0.130 125.227 -0.132
202212 -0.140 125.222 -0.142
202303 -0.100 127.348 -0.100

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CTI BioPharma  (NAS:CTIC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


CTI BioPharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of CTI BioPharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CTI BioPharma (CTI BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
3101 Western Avenue, Suite 800, Seattle, WA, USA, 98121
CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.
Executives
James K Fong officer: EVP & Chief Commercial Officer C/O CTI BIOPHARMA CORP, 3101 WESTERN AVENUE, SUITE 800, SEATTLE WA 98121
Adam R Craig director, officer: President and CEO C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
David Kirske officer: EVP, Chief Financial Officer C/O CTI BIOPHARMA CORP., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Michael A Metzger director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Diane L. Parks director 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Matthew D Perry director ONE SANSOME STREET, 30TH FLOOR, SAN FRANCISCO CA 94104
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Laurent Fischer director C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
David Ross Parkinson director C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY SUITE 300, SOUTH SAN FRANCISCO CA 94080
Richard L Love director
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104